LTRN
Income statement / Annual
Last year (2024), Lantern Pharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Lantern Pharma Inc.'s net income was -$20.78 M.
See Lantern Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$174.84 K
|
$0.00
|
$0.00
|
$0.00
|
$1.63 K
|
-$2.54 K
|
| Gross Profit |
$0.00
|
-$174.84 K
|
$0.00
|
$0.00
|
$0.00
|
-$1.63 K
|
$2.54 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$16.13 M
|
$11.89 M
|
$8.60 M
|
$7.57 M
|
$2.24 M
|
$953.19 K
|
$572.10 K
|
| General & Administrative Expenses |
$6.09 M
|
$5.98 M
|
$5.83 M
|
$5.02 M
|
$3.66 M
|
$1.48 M
|
$1.15 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.09 M
|
$5.98 M
|
$5.83 M
|
$5.02 M
|
$3.66 M
|
$1.48 M
|
$1.15 M
|
| Other Expenses |
$0.00
|
-$174.84 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$22.22 M
|
$17.70 M
|
$14.43 M
|
$12.59 M
|
$5.91 M
|
$2.43 M
|
$1.73 M
|
| Cost And Expenses |
$22.22 M
|
$17.88 M
|
$14.43 M
|
$12.59 M
|
$5.91 M
|
$2.43 M
|
$1.73 M
|
| Interest Income |
$742.36 K
|
$765.39 K
|
$204.36 K
|
$67.93 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$204.36 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$17.28 K
|
$174.84 K
|
$10.08 K
|
$6.76 K
|
$3.39 K
|
$1.63 K
|
-$2.54 K
|
| EBITDA |
-$22.20 M |
-$15.79 M |
-$14.42 M |
-$12.58 M |
-$5.90 M |
-$2.43 M |
-$1.73 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.44 M
|
$1.92 M
|
$172.81 K
|
$228.48 K
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$20.78 M
|
-$15.96 M
|
-$14.26 M
|
-$12.36 M
|
-$5.91 M
|
-$2.43 M
|
-$1.73 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.54 K
|
| Net Income |
-$20.78 M
|
-$15.96 M
|
-$14.26 M
|
-$12.36 M
|
-$5.91 M
|
-$2.43 M
|
-$1.73 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1930.92 |
-1.47 |
-1.31 |
-1.13 |
-0.95 |
-0.39 |
-0.28 |
| EPS Diluted |
-1930.92 |
-1.47 |
-1.31 |
-1.13 |
-0.95 |
-0.39 |
-0.28 |
| Weighted Average Shares Out |
$10.76 M
|
$10.84 M
|
$10.85 M
|
$10.90 M
|
$6.22 M
|
$6.27 M
|
$6.22 M
|
| Weighted Average Shares Out Diluted |
$10.76 M
|
$10.84 M
|
$10.85 M
|
$10.90 M
|
$6.22 M
|
$6.27 M
|
$6.22 M
|
| Link |
|
|
|
|
|
|
|
